The U.S. central lab market exceeded USD 370 billion in 2025 and is projected to reach approximately USD 620.13 billion by 2035, growing at a CAGR of 5.30%, driven by rising clinical trial activity, advanced diagnostics, and increasing demand for efficient lab services.

U.S. Central Lab Market Statical Scope

The U.S. Market plays a crucial role as it offers standardized, high-quality analytical testing, biomarker analysis, and specimen management that are necessary to expedite pharmaceutical research, drug development, and clinical trials, supporting over 70% of global trials. It guarantees consistency and adherence to regulatory standards for new therapies while managing the increasing complexity associated with personalized medicine and oncology . The surge in complex studies, such as gene therapies and immuno-oncology, necessitates specialized, high-capacity laboratories capable of conducting advanced, standardized tests across extensive, multisite trials. As a prominent center for research and development, the U.S. market reaps the benefits of leading companies, sophisticated infrastructure, and substantial investment, positioning it as a key player in global progress in personalized medicines.

U.S. Central Lab Market Share, By Services, 2025 (%)

• Genetic Services - The Genetic Services segment plays a vital role in the U.S. central lab market as it is the fastest-growing area, fueled by the rise of precision medicine, oncology trials, and next-generation sequencing (NGS). This segment accounts for a 20% share.
• Biomarker Services - The biomarker services segment is the largest and also the fastest-growing part of the market, crucial for speeding up drug development, facilitating precision medicine, and assessing therapeutic effectiveness in clinical trials. It holds a dominant 39% share.

U.S. Central Lab Market Share, By End-use, 2025 (%)

• Pharmaceutical Companies - The pharmaceutical company segment is essential to the U.S. Market because it has the largest market share, driven by a strong demand for outsourced, standardized testing in global clinical trials, biologics, and oncology research. It dominates with a 45% share.
• Biotechnology Companies - The biotechnology company segment is an important and rapidly growing part of the Market due to its significant dependence on outsourced, specialized testing for complex biologics, gene therapies, and oncology clinical trials. This segment holds a 35% share.

Top Companies in the U.S. Central Lab Market

• ACM Global Laboratories
• Labconnect
• Cerba Research
• Eurofins Scientific
• Medicover Integrated Clinical Services (MICS) (Synevo Central Labs
• Versiti (Cenetron)
• A.P. Møller Holding A/S (Unilabs)
• Ampersand Capital Partners (Pacific Biomarkers)
• Lambda Therapeutics Research Ltd
• Cirion Biopharma Research Inc.

Segments Covered in the Report

By Services

• Genetic Services
• Biomarker Services
• Microbiology Services
• Anatomic Pathology/ Histology
• Specimen Management & Storage
• Special Chemistry Services

By End-use

• Pharmaceutical companies
• Biotechnology Companies
• Academic and Research Institutes